Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Boswellia for Urinary Toxicity in Prostate Cancer Radiotherapy
NCT07867158Phase 2Not yet recruiting
- Sponsor
- Brigham and Women's Hospital
- Start
- Oct 2026
- Primary completion
- Apr 2027
01
Overview
A Phase 2 trial of boswellia serrata in urinary toxicity (UT), sponsored by Brigham and Women's Hospital. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
boswellia serrata
03
Conditions
urinary toxicity (UT)
Beyond the preview
Go deeper on NCT07867158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07867158.